NGS-based RNA-sequencing Market Size, Share, Trends, Growth 2034

NGS-Based RNA-Sequencing Industry Prospective:

The global NGS-based RNA-sequencing market size was worth around USD 2.46 billion in 2024 and is predicted to grow to around USD 14.71 billion by 2034, with a compound annual growth rate (CAGR) of roughly 19.60% between 2025 and 2034.

Request Free Sample

NGS-Based RNA-Sequencing Market: Overview

Next-generation sequencing (NGS) of ribonucleic acid (RNA) is an advanced sequencing technology used to identify and analyze RNA in a research sample. NGS-based RNA-sequencing allows scientists and research teams to learn and understand the complete set of RNA molecules, also known as transcriptomes.

The data thus obtained is further used to study gene expression. It is also used to identify any potential mutation or novel transcripts, helping researchers conduct a molecular-level study of biological processes. NGS-based RNA-sequencing has multiple applications in the modern world. Healthcare agencies and drug developers primarily use it to develop new therapies and treatment programs.

On the other hand, next-generation sequencing of RNA is also used in the agriculture sector to study crops and their responses to changes in climate conditions.

During the forecast period, the industry for NGS-based RNA-sequencing is expected to gain significant growth momentum. Increasing focus on developing climate-resistant crops will emerge as a crucial growth driver for the industry. However, exorbitant prices associated with the technology may limit the industry’s expansion rate.

Key Insights:

• As per the analysis shared by our research analyst, the global NGS-based RNA-sequencing market is estimated to grow annually at a CAGR of around 19.60% over the forecast period (2025-2034)
• In terms of revenue, the global NGS-based RNA-sequencing market size was valued at around USD 2.46 billion in 2024 and is projected to reach USD 14.71 billion by 2034.
• The NGS-based RNA-sequencing market is projected to grow at a significant rate due to the rising applications in cancer research and immunotherapy.
• Based on the product & service, the RNA-sequencing platforms & consumables segment is growing at a high rate and will continue to dominate the global market as per industry projections.
• Based on the end-user industry, the research & academia segment is anticipated to command the largest market share.
• Based on region, North America is projected to dominate the global market during the forecast period.

NGS-Based RNA-Sequencing Market: Growth Drivers

Rising applications in cancer research and immunotherapy to drive market demand rate

The global NGS-based RNA-sequencing market is expected to be driven by the rising applications of the technology in cancer research. Additionally, next-generation RNA sequencing has also played a crucial role in revolutionizing cancer immunotherapy.

In cancer research, the technology is used to identify genes or mutations that appear in cancer cells. The information obtained can assist drug companies in developing a more targeted approach toward diagnosing or treating the condition.

Moreover, NGS-based RNA-sequencing has also proven pivotal in developing effective immunotherapy solutions by identifying biomarkers confirming patient response to a certain treatment. Cancer is one of the world’s leading causes of medically-caused deaths worldwide. It affects millions of people worldwide across age groups.

Current cancer diagnostic and treatment programs have failed to deliver the expected results, as the fatality rate due to cancer continues to grow every year. It has led to an increased demand for funding for cutting-edge cancer-related research.

Increased demand for climate change-resistant crops to generate market revenue in the long run

Rapid industrialization, globalization, and urbanization have amplified climate change worldwide. Weather conditions globally are changing rapidly, including frequent cases of extremely prolonged droughts and floods. Furthermore, increasing global temperature has impacted agricultural yield across countries.

According to industry research, the global NGS-based RNA-sequencing market is expected to gain momentum as research companies continue to invest in developing climate change-resistant crops. Agriculture, biotechnology, and plant breeding have leveraged the offerings of RNA sequencing to improve crop yield and resilience against pest infection or weather changes.

NGS-Based RNA-Sequencing Market: Restraints

High cost of technology application to limit the market expansion rate during the projection period

The global NGS-based RNA-sequencing industry is expected to be restricted by the high cost of technology development and end-user applications.

Next-generation sequencing machines are expensive. NGS equipment with medium throughput used in research facilities can cost anywhere between USD 100,000 and USD 500,000. They also required skilled professionals to optimally utilize the tools.

Furthermore, most NGS-based RNA-sequencing solution providers are required to invest in high-performance computers and data storage systems. These factors increase the total cost of utilizing the technology in the long run.

NGS-Based RNA-Sequencing Market: Opportunities

Continuous technological advancements in the industry to generate market growth opportunities

The global NGS-based RNA-sequencing market is expected to generate growth opportunities due to the ongoing technological advancements in the industry. In February 2025, Roche, a multinational healthcare company, announced the launch of a proprietary, cutting-edge sequencing by expansion (SBX) technology.

With this launch, the company has established a new range of NGS solutions in the market. SBX chemistry works in tandem with sensor modules to deliver high-throughput and ultra-rapid sequencing. SBX leverages a revolutionary biochemical process that encodes the sequence of target nucleic acid molecules into a more quantitative and measurable polymer called an Xpandomer.

In December 2024, Alithea Genomics, a global leader in terms of large-scale RNA sequencing and transcriptomics, launched MERCURIUS™ Full-Length DRUG-seq library preparation technology. The first-of-its-kind technology integrates an extraction-free workflow, massive sample multiplexing, and full transcript coverage in a one-of-its-kind RNA-sequence workflow.

The technology can be used for up to 384 samples. It also delivers exceptional cost-efficiency and reduced processing time. Market players are focusing on developing solutions that can conduct single-cell & spatial transcriptomics as well as third-generation sequencing.

NGS-Based RNA-Sequencing Market: Challenges

Ethical concerns over the use of patients’ genetic information may challenge market expansion

The global NGS-based RNA-sequencing industry is expected to be challenged by growing ethical concerns. RNA sequencing utilizes the genetic information of patients. Companies comply with regional regulations to protect the genetic information of the patients. However, several questions have been raised in the research field over the appropriate use of the genetic compositions of a patient for research purposes.

Request Free Sample

NGS-Based RNA-Sequencing Market: Report Scope

NGS-Based RNA-Sequencing Market: Segmentation

The global NGS-based RNA-sequencing market is segmented based on product & service, technology, end-user industry, and region.

Based on the product & service, the global market divisions are RNA-sequencing platforms & consumables, sample preparation products, data analysis, storage, & management, and RNA sequencing services.

In 2024, the highest demand was listed in the RNA-sequencing platforms & consumables segment. The growth rate is a result of increased demand for the platforms across research facilities and laboratories.

Furthermore, some of the components, such as flow cells and reagents, draw consistent revenue. The segment is expected to deliver a CAGR of over 6% during the projection period.

Based on technology, the global NGS-based RNA-sequencing industry is led by nanopore sequencing, single-molecule real-time sequencing, ion semiconductor sequencing, and sequencing by synthesis.

Based on the end-user industry, the global market divisions are pharmaceutical & biotechnology companies, hospitals & clinics, research & academia, and others. In 2024, the research & academia segment was the leading revenue generator.

The increasing demand for transcriptomics research to understand disease mechanisms, gene expression, and other biological traits of RNA will fuel segmental revenue in the coming years. During the forecast period, the segment is anticipated to deliver a CAGR of more than 7.01%.

NGS-Based RNA-Sequencing Market: Regional Analysis

North America to take the lead during the forecast period

The global NGS-based RNA-sequencing market will be led by North America during the forecast period. The US will emerge as the highest revenue generator in the regional market.

The North American growth rate will be the result of increased research spending on RNA sequencing for gene-based studies. The regional drug-developing companies and biotechnology organizations will continue to contribute to North America’s revenue in the coming years.

In March 2024, Foundation Medicine, Inc., announced the US launch of FoundationOne®RNA. The novel tissue-based RNA sequencing technology is used for detecting cancer fusions covering around 318 genes.

In January 2024, QIAGEN Digital Insights (QDI), the biotechnology wing of QIAGEN, launched the next-generation QIAGEN CLC Genomics Workbench platform equipped with LightSpeed technology. The tool now supports NGS for secondary analysis of somatic cancer. The regional market will further be affected by increased funding for cancer research.

The US is one of the world’s most advanced countries in terms of cancer care. The presence of prestigious cancer research facilities in the US will also emerge as the leading regional market growth driver.

NGS-Based RNA-Sequencing Market: Competitive Analysis

The global NGS-based RNA-sequencing market is led by players like:

• Pacific Biosciences of California Inc.
• Illumina Inc.
• 10x Genomics Inc.
• GATC Biotech AG
• Thermo Fisher Scientific Inc.
• Eurofins Scientific
• Macrogen Inc.
• Agilent Technologies Inc.
• Takara Bio Inc.
• Oxford Nanopore Technologies Ltd.
• Novogene Corporation
• PerkinElmer Inc.
• BGI Genomics Co. Ltd.
• QIAGEN N.V.
• Bio-Rad Laboratories Inc.

The global NGS-based RNA-sequencing market is segmented as follows:

By Product & Service

• RNA-Sequencing Platforms & Consumables
• Sample Preparation Products
• Data Analysis
• Storage, & Management
• RNA Sequencing Services

By Technology

• Nanopore Sequencing
• Single-Molecule Real-Time Sequencing
• Ion Semiconductor Sequencing
• Sequencing By Synthesis

By End-User Industry

• Pharmaceutical & Biotechnology Companies
• Hospitals & Clinics
• Research & Academia
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa